@article{JTD24325,
author = {Lindsey Russell and Tanya Monaghan and Dina Kao},
title = {The need to move away from fecal transplant towards targeted, refined microbiome therapy},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {10},
year = {2018},
keywords = {},
abstract = {The recent editorial entitled “Microbiota replacement for Clostridium difficile by capsule is as effective as via colonoscopy” by Saha & Khanna provides an excellent review of the clinical efficacy, as well as the delivery options, for fecal microbiota transplantation (FMT) for patients suffering from a recurrent, C. difficile infection (rCDI) (1). The review also highlights the uncertainty that is relating to the optimal dose, or the delivery route for FMT (1). Admittedly, FMT is a crude and archaic method, with many drawbacks despite the high efficacy and lack of short term safety concerns. The long-term consequences remain to be determined, as the potentials for transferring infectious agents, or donor traits such as obesity, exist.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/24325}
}